After reports claimed that filings in patent offices in India, the US, and Europe did not mention ICMR or its scientists, but only BBIL and its scientists, the Hyderabad-based biotechnology......
Bharat Biotech International Limited on Tuesday said its COVID-19 intranasal vaccine iNCOVACC, which is now available on CoWIN portal, is priced at Rs 800 (excluding GST) for private markets and Rs......
Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday.......
The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's intranasal Covid vaccine for restricted emergency use in those aged above 18 years. "Big Boost to India's Fight......
Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe. Photograph:......
Budget 2025 represents a crucial step towards empowering our youth, nurturing a sustainable startup ecosystem, and establishing India as a global leader in agriculture, medical tourism, and......
India witnessed a record-breaking surge in deal activity in February, with 226 M&A and private equity deals totaling $7.2 billion -- the highest monthly deal volume in the last three years,......
Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed. Hyderabad based Bharat Biotech, whose Covid-19 vaccine......
The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results, reports Sohini Das. Photograph: Kind courtesy Bharat Biotech ......
Close on the heels of Hetero Drugs launching Oseltamivir, an anti-bird flu drug, Nasdaq-listed Novavax Inc and Hyderabad-based Bharat Biotech International on Monday announced a strategic......